Available Expanded Access NCT04799522
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)
Sponsor: Sanofi
Conditions
Sphingomyelin Lipidosis
Interventions
olipudase alfa (GZ402665)
Updated 1 time since 2021 Last updated: Mar 11, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT04799522, this observational or N/A phase trial focuses on Sphingomyelin Lipidosis and remains ongoing. Sponsored by Sanofi, it has been updated 1 time since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Available
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sanofi
Data source: Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.